AGC
AGC, the provider of a wide range of solutions from automotive and display glass to the cutting-edge materials essential for next-generation mobility, will exhibit at CES2023, the world's leading technology trade show, being held in Las Vegas during January 3-8, 2023. The 3rd and 4th will be reserved for media and pre-show keynotes; the fair will be open to the public from the 5th. The company will exhibit 17 of its products, including several brand new releases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221204005064/en/
AGC‘s booth at CES2023 (#4377, Vehicle Tech & Advanced Mobility, LVCC - West Hall) (Graphic: Business Wire)
AGC has been a leading manufacturer of architectural, automotive and display glass for more than 110 years, supplying high-quality products worldwide. Today, the company leverages its technological expertise in the fields of glass, electronics, chemicals, and ceramics to provide a variety of cutting-edge materials and services that meet the growing demand for autonomous driving and other mobility services.
One of the highlights of AGC’s exhibits at CES will be the company’s FIR (far infrared) camera-compatible windshield, featuring special glass that allows far-infrared rays to penetrate, something which ordinary automotive glass does not. This allows sensor fusion of regular visible and FIR cameras mounted behind the windshield and reduces the risk of accidents involving pedestrians and cyclists at night or in bad weather.
Another highlight of the exhibit will be AGC’s glass composition and processing technologies; these provide the strength and optical capabilities needed to mount and deploy the cameras and the LiDAR (light detection and ranging) components required for autonomous driving. A wide range of other solutions will also be exhibited, including the 5G-sub6 Glass Antenna and the 3D Curved Cover Glass For Automotive Interior Displays. For a complete list, please refer to the Appendix.
Yoshinori Hirai, President & CEO of AGC, commented, “CES is one of the world's most influential technology trade shows, and we see it as the best stage on which to showcase AGC's capabilities to the world. We strongly believe our next-generation mobility-related products and solutions will create a buzz among CES visitors. The materials we offer have an appeal that can only be successfully conveyed when they are seen and experienced up close. We hope that as many people as possible will learn firsthand about the value we offer and make good use of our products.”
Please stop by our booth and see the various ways in which AGC is pushing the boundaries of technology. If you would like to interview an AGC spokesperson, please contact us.
Booth information
LVCC - West Hall
Vehicle Tech & Advanced Mobility
#4377
In the same West Hall there will be a separate booth (#6557) dedicated to our "Wideye" solutions and another for our "FeelinGlass" product (#6674).
About CES
Owned and produced by the Consumer Technology Association (CTA)®, CES® is the world’s most influential tech event; the proving ground for breakthrough technologies and global innovators where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. CES 2023 will showcase the latest technological innovations dedicated to addressing the world’s most pressing global challenges in support of the United Nations’ efforts to advance human security for all. Please visit https://www.ces.tech/ for further details.
About AGC Inc.
AGC Inc. (Headquarters: Tokyo, President & CEO: Yoshinori Hirai) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Building on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The Group employs some 56,000 people worldwide and generates annual sales of around 1.7 trillion Japanese yen (approx. US$ 12.3bn) through its operations in more than 30 countries and regions. For more information, please visit https://www.agc.com/en/index.html
Appendix (List of exhibited products and technologies)
Product Name |
Brand name |
Usage/Application |
Appearing for the first time? |
Features |
FIR (far infrared) camera-compatible windshield |
|
Automotive windshields |
Yes |
|
5 G-sub 6 Glass Antenna |
|
Automotive Glazing |
Yes |
|
3D Curved Cover Glass
|
|
Automotive Interior Display
|
No |
Anti-reflection / Anti-fingerprint coating |
Porous Aminosilica |
|
CO2 Direct Air Capture (DAC) / Acid gas removal /
|
Yes |
|
Thermal Conductive-Electrical Insulation Film |
|
Thermal interface material for power semiconductors |
Yes |
|
Super-Hydrophobic Glass |
|
Window and roof glass for mobility applications;
|
Yes |
|
Windshield damage detection smart sensor |
Jack by AGC |
Self-powered device that detects, diagnoses and notifies in real-time glass damage to windshields |
Prototype has been previously presented |
|
Glass B-Pillar With Invisible Sensor Integration |
Wideye by AGC |
Lateral integration of a LiDAR sensor in a B-Pillar made of infrared transparent glass |
Prototype has been previously presented |
|
Cover Glass |
EG-A1, EG-A2 |
LiDAR, Camera |
Yes |
|
Aspherical Glass Lenses |
Aspherical Glass Molded Lenses |
LiDAR, Camera, Projector, Optical communication, AR/VR/MR, Lighting |
No |
|
Optical Filter |
IR Pass Filter, Band Pass Filter, Mirror |
Cover/noise removal for LiDAR, Camera, UV disinfection, semiconductor manufacturing |
No |
|
Glass Ceramics Substrate |
GCHPTM |
LEDs, semiconductors, lasers |
No |
|
DOE and Diffuser |
DOE and diffuser |
ToF sensor, LiDAR, cameras, projectors, optical communication, AR/VR/MR, lighting |
No |
|
Anti-glare glass |
New AG (anti-glare) glass for high-definition panels |
High-definition notebook PCs, tablets and monitors |
Yes |
|
Chemically engineered high strength glass |
Dragontrail |
Cover glass for displays of smartphones, tablets, PCs, etc. (electronic devices requiring cover glass) |
No |
|
FWA antenna |
"5G Millimeter Wave Transparent Antenna for FWA " |
Antenna is thin and transparent,
|
No |
|
Transparent Reflector Fence |
|
Local 5G networks |
Yes (overseas) |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221204005064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom